Rain Oncology Inc
Rain Oncology Inc., based in Newark, California, specializes in developing innovative targeted therapies aimed at helping cancer patients regain their quality of life. The company focuses on identifying patients with specific genetic markers who are most likely to benefit from their treatment options, particularly in MDM2-dependent TP53 wildtype cancers.
The firm's leading oral agent, milademetan, targets the MDM2-p53 interaction, a critical factor in many malignancies, and is currently in clinical development. Rain Oncology's recent activities include a merger agreement with Pathos AI, which indicates ongoing advancements in their corporate strategy and research endeavors.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.